Today's Live Updates on Q4 Results 2025: Swiggy, Dr. Reddy's, Reliance Power, Bank of India, and other notable entities are set to unveil their Q4 financial figures.
Brace yourself for a barrage of Q4 earnings results, as a plethora of companies from various sectors are about to unveil their financial performance for FY25! Today's lineup includes Swiggy, Dr Reddy's Laboratories, Manappuram Finance, Reliance Power, Relaxo Footwears, Novartis India, Dhanlaxmi Bank, Bank of India, and many others.
Top Performers and Sector Trends
As per the analysis by Anand Rathi Research Team, while near-term uncertainties persist, a constructive medium-to-long-term outlook remains due to robust macroeconomic fundamentals, steady earnings trajectory, and attractive valuations.
This rosy forecast indicates a favorable backdrop for selective stock-picking, with large caps and midcaps favored over small caps. Sectors like autos, apparel retail, and staples are expected to underperform, while jewellery retail, value retail, hospitality, healthcare, and large-ticket consumer durables could outperform.
Key risks include short-term volatility, which is anticipated to persist amid ongoing geopolitical tensions.
Dr Reddy's Laboratories: A Prominent Player
Dr Reddy's Laboratories is primed for strong revenue and profit growth, powered by strategic acquisitions and a stable market performance. Here's a breakdown of their expected Q4 FY25 figures:
- Revenue: Approximately Rs 8,328.26 crore, up by roughly 17.07% year-on-year (YoY) compared to Q4 FY24.
- Net Profit: Projected net profit within the range of Rs 1,324 crore to Rs 1,456.5 crore, signifying a YoY increase of up to 18.6%.
Key drivers for Dr Reddy's expected growth include the integration of the Nicotinell acquisition, consistent performance in the US market, positive domestic business momentum, and the Sanofi vaccine integration expected to boost growth in India.
Analysts have mixed opinions on Dr Reddy's performance, with 15 buys, 11 holds, and 14 sells on the stock.
Swiggy: A Food Giant's Q4 Showdown
Swiggy, the food delivery giant, is anticipated to report revenue of around Rs 4,227 crore for Q4 FY25. Despite the robust growth, losses are expected to increase due to higher discounts, increased delivery costs, and escalated marketing expenses.
Swiggy's focus remains intensely centered on customer acquisition, and the impact of seasonal demand on operational metrics remains to be seen. The company's aggressive customer acquisition strategies may lead to profitability challenges.
Stay Tuned for More Updates!
Join us as we eagerly await the Q4 results from these companies, and keep an eye out for additional insights and updates. Let's delve into the world of Q4 earnings and uncover valuable investment opportunities together!
- The Q4 earnings results for various companies are about to be announced, including Swiggy, Dr Reddy's Laboratories, and others, providing insights into their financial performance for FY25.
- Analysts predict a favorable backdrop for selective stock-picking, with large caps and midcaps favored over small caps due to robust macroeconomic fundamentals, steady earnings trajectory, and attractive valuations.
- Dr Reddy's Laboratories is expected to show strong revenue and profit growth due to strategic acquisitions and a stable market performance, with revenue approximately Rs 8,328.26 crore and net profit within the range of Rs 1,324 crore to Rs 1,456.5 crore for Q4 FY25.
- Key drivers for Dr Reddy's expected growth include the integration of the Nicotinell acquisition, consistent performance in the US market, positive domestic business momentum, and the Sanofi vaccine integration expected to boost growth in India.
- Swiggy, the food delivery giant, is anticipated to report revenue of around Rs 4,227 crore for Q4 FY25 but losses are expected to increase due to higher discounts, increased delivery costs, and escalated marketing expenses.
- The ongoing geopolitical tensions may lead to short-term volatility, which could persist in the market.
- As per the analysis by Anand Rathi Research Team, sectors like autos, apparel retail, and staples are expected to underperform, while jewellery retail, value retail, hospitality, healthcare, and large-ticket consumer durables could outperform.
- To stay updated on Q4 earnings results and valuable investment opportunities, join our journey and stay tuned for additional insights and updates.
